Small Peptides for Alzheimer's: How Tiny Molecules Could Restore Memory

Narrative review examining the mechanisms of action of four small peptides with demonstrated potential in alleviating Alzheimer's-related symptoms, along with evaluation of delivery systems that enhance their therapeutic efficacy, including intranasal routes, nanoparticle encapsulation, and chemical stabilization approaches.

Current Alzheimer's treatments mostly manage symptoms without addressing the underlying synaptic damage. Small peptides can interact with the specific molecular pathways driving the disease — amyloid buildup, tau tangles, and synapse loss. Combined with new delivery technologies, they represent a fundamentally different approach to slowing or potentially reversing cognitive decline in Alzheimer's patients.

While antibody-based Alzheimer's treatments like lecanemab have recently gained approval, small peptides offer potential advantages — they're cheaper to make, easier to modify, and can cross biological barriers that larger molecules cannot. This research direction could eventually yield more accessible and targeted Alzheimer's therapies.

As a narrative review, this paper synthesizes existing preclinical and early-stage evidence rather than reporting new experimental data. Most of the peptide candidates discussed have not yet been tested in large human clinical trials. The review does not provide quantitative outcome data or statistical comparisons between delivery methods.